Primmune Therapeutics

Primmune Therapeutics develops oral TLR7 agonists to enhance cancer immunotherapy

Biotech & Life Sciences

Sector

Seed

Stage

Biopharmaceutical

Model

01Company Overview

Primmune Therapeutics develops oral TLR7 agonists to enhance cancer immunotherapy.

02Backed By1 investor

03Similar Companies

CP

Corvus Pharmaceuticals

Biotech & Life Sciences

→

TT

IT

FB

RT

04Startup DNA

9

signals

Sectors
Business Model
Technology